Ying Feng

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

Yuqiao Shen, Farah Rehman, Ying Feng et al. · Clinical Cancer Research · 2013 · 487 citations · Full text

Medicine, Oncology, Pharmacology +14

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

Junko Murai, Ying Feng, Guoying Karen Yu et al. · Oncotarget · 2016 · 292 citations · Full text

Medicine, Oncology, Pharmacology +13

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

C. Allison Stewart, Pan Tong, Robert J. Cardnell et al. · Oncotarget · 2017 · 227 citations · Full text

Medicine, Oncology, Pharmacology +17

ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with β-catenin defects and promotes neoplastic transformation

Frank T. Kolligs, Marvin T. Nieman, Ira Winer et al. · Cancer Cell · 2002 · 157 citations · Full text

Medicine, Molecular Biology, Oncology +17

The Core Protein of Glypican Dally-Like Determines Its Biphasic Activity in Wingless Morphogen Signaling

Dong Yan, Yihui Wu, Ying Feng et al. · Developmental Cell · 2009 · 114 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +9